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Abstract
Human papillomavirus type 16 (HPV16) E7 is a viral oncoprotein believed to play a major role in cervical cancer. In this study,
an antagonist peptide against HPV16E7 protein was first identified from screening the c7c phage display peptide library.
The binding specificity and affinity of the selected peptide to HPV16E7 were tested by competitive enzyme-linked
immunosorbent assay (ELISA). The antagonist peptide showed obvious anti-tumor efficacy both in cell lines and animal
tumor models. Significant cell proliferation inhibition with high specificity was noted when HPV16-positive cells were
treated with the peptide. This anti-tumor efficacy was resulted from overriding the activities of HPV16E7 and reactivating
the pRb/E2F pathway, as shown by a series of experiments. Flow cytometry analysis revealed that the selected peptide
induced G1 arrest in a dose-dependent manner. Competitive ELISA, pull down, and Co-IP experiments indicated that the
selected peptide disrupted the interaction between HPV16E7 and pRb proteins both in vitro and in vivo. Luciferase reporter
assay verified that transcription activities of E2F were suppressed by the peptide through restoration of pRb. RT-PCR and
Western blot revealed that it reduced cyclins A, D1, and E1 expression, and led to HPV16E7 protein degradation, but pRb
protein stabilization. The current study suggests that this specific peptide may serve as a potential therapeutic agent for
HPV16-positive cervical cancer.
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Introduction
Cervical cancer is the second leading cause of cancer death in
women worldwide. In the past 20 years, a large number of studies
have suggested that the role of high-risk human papillomavirus
(HPV) is critical for the occurrence and development of cervical
cancer [1]. Several reports stated that HPV was detected in 99.7%
of cervical tumor specimens, 50–60% of which were HPV 16-
positive [2,3,4]. HPV E6 and E7 have been proven to play
important roles in malignant transformation. They are expressed
in HPV-transduced cells to inactivate tumor suppressor proteins
such as p53 and pRb, respectively, leading to cell cycle disorder,
telomerase activation, and cell immortalization. Their continued
expression is essential for the malignant transformation and
maintenance of tumor cells [5,6,7,8,9].
High-risk HPV E7 associates with the retinoblastoma family of
proteins (pRb, p107 and p130), induces their ubiquitin-mediated
proteolysis, and disrupts their association with the E2F family of
transcription factors, subsequently transactivating cellular proteins
required for DNA replication. Moreover, E7 binds and induces the
proteasome-mediated degradation of pRb, p107 and p130 proteins
[10,11,12,13,14,15,16]. Additional E7-interacting proteins have
been found in recent years, including transcription factors p300,
CBP and pCAF [17,18]. More recently, E7 has been shown to
interact with a pRb-associated protein, p600 [19,20] and induce
genetic instability, predominantly via its ability to induce abnormal
centrosome numbers and multipolar mitotic spindles [21].
As these viral proteins are not expressed in normal cells, E7
protein has become an important research target for HPV
therapy. Strategies for achieving specific and selective abrogation
of E7 protein have been proposed as a rational therapeutic
approach for HPV-positive carcinoma of the cervix [22]. A few
studies have shown that antisense and peptide aptamers targeting
HPV E6/E7 can induce target cell apoptosis [23,24,25].
Therefore, finding inhibitory peptides that target E7 and rescue
the tumor-suppressing activity of pRb may be one of the notable
means of therapy for HPV-positive cervical carcinoma.
In this study, we screened for HPV16E7 antagonists from a
C7C phage library, and a new peptide, which specifically binds to
the HPV16E7 protein, was selected. The peptide repressed the
proliferation of HPV16-positive cervical carcinoma cells selective-
ly. The proliferation inhibition was associated with cell cycle arrest
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17734and function restoration of pRb, which suppresses E2F transacti-
vation and down-regulates a group of cell-cycle progressing-related
genes, including cyclins A, D and E. More encouragingly,
subcutaneous tumor model experiments demonstrated that the
peptide could suppress the tumor xenografts growth significantly.
In light of these results, there is a strong evidence to consider this
selected peptide a ‘‘good candidate’’ for the treatment of HPV16-
positive cancer.
Results
Phage Display Screening and Peptides Synthesis
The full-length HPV16E7 protein was expressed in E. coli
BL21 and purified by immobilized-metal affinity chromatography
on Ni-NTA agarose beads as instructed by the manufacturer and
was used as a target for the panning of a random heptapeptide
phage display library. After three rounds of bio-panning, nearly
1610
3 enrichments of positive-binding clones were yielded. The
isolated phage clones’ ability to bind to the HPV16 E7 protein
was tested by ELISA. Seven of the 40 isolated clones showed high
absorbance values in the ELISA assay (.36absorbance values of
control). They were identified as positive phage clones (data not
shown).
The nucleotide sequences coding for peptides on the positive
phage clones were determined by Shanghai Sangon Biological
Engineering Technology and Service Co., Ltd. (Shanghai, P.R.
China). Results showed that all eight clones we obtained from the
screening had the same sequence PKGLDWC. In data bank
searches, we did not find any obvious similar sequences in
naturally occurring E7 binding proteins, including pRb, or human
proteins. The corresponding peptide SACPKGLDWCGG (C&C
bridged by disulfide bonds), without or with 5-FAM labeling, were
chemically synthesized for further study (named ‘‘Pep-7’’ and ‘‘F-
pep,’’ respectively). The peptide with the same amount, but
random sequence, of amino acids was synthesized as negative
control peptide (named ‘‘N-pep’’).
Both the Positive Clones and Selected Peptide Pep-7
Have Specific Affinity to HPV16E7
The specificity affinities of the positive clones and Pep-7 were
determined by competitive ELISA. Positive clone B-5 and B-9 and
library phages (negative control) at concentrations of 10
13 CFU/
ml to 10
5 CFU/ml were mixed with HPV16E7 mAb, and then
incubated with the coated E7 protein. HPV16E7 mAb alone,
incubated with the coated E7 protein, gave the benchmark
absorption value. Absorbance values and inhibitory ratio were
collected and calculated as outlined in Materials and Methods.
Both clones B-5 and B-9 were revealed to have high affinities for
binding to the HPV16 E7 protein. The binding inhibitory ratio of
both clones at the concentration of 10
13 CFU/ml were higher
than 50%, while the negative control phage had a very low
inhibitory rate (,5%, Figure 1A).
Similarly, Pep-7 and N-pep (as negative controls) at concentra-
tions of 0.08 mM to 800 mM were used to compete with HPV16
E7 or HPV18 E7 antibodies for binding to their antigens. As
shown in Figure 1B, the Pep-7 bound to HPV16 E7 with high
affinity compared with the control peptide N-pep but did not bind
to HPV18 E7. The differences between the binding affinities of
Pep-7 to HPV16E7 and HPV18E7 were statistically significant
(p=0.004). Likewise, differences between the binding affinities of
Pep-7 and N-pep to HPV16E7 were statistically significant
(p=0.015). Results revealed that the synthesized peptide Pep-7
had similar characteristics with the positive phage clones, binding
to HPV16 E7 specifically.
Peptide Internalization and Distribution
The green fluorescent labeled ‘‘F-pep’’ was used to monitor
cell uptake and intracellular location of the peptide. As shown in
Figure 2B, when incubated with SiHa cells at 37uC, the peptide
was uptaken by more than 96% cells after 8 h. Almost SiHa
cells uptook the peptide after 24 h incubation. Visualization
under fluorescence microscope indicated that F-pep was
distributed in both cytoplasm and nucleus, which coincides
with the subcellular location of HPV16 E7 protein (see
Figure 2A) [26]. In contrast, cells incubated with equimolar 5-
Fam did not show fluorescence. These results suggested that the
peptide had strong cell-penetrating power, and it bound to E7 in
SiHa cells.
The Peptide Pep-7 Suppresses Cell Proliferation in HPV16
Positive Cell Lines
To determine whether the peptide could interfere with the
growth of HPV16-positive mammalian cells, we first tested the
effect of Pep-7 on the proliferation of HPV16-positive cervical
carcinoma cells CaSki, SiHa and the HPV18-positive cervical
cancer cell line HeLa by MTT at different time points, as
indicated in Figure 3. The proliferation of HPV16-positive cells
was repressed significantly by Pep-7 in a dose- and time-dependent
manner (Figure 3A), but not by the negative control peptide N-pep
(Figure 3C). On the other hand, Pep-7 could not repress the
proliferation of HeLa cells (Figure 3B). The effect of Pep-7 on the
proliferation of other HPV-negative cell lines including CNE,
HaCat, Cos7, and NIH 3T3, was also tested. Again, Pep-7 showed
negligible effect on these cells (data not shown).
The specific growth suppression of Pep-7 was further assessed
by colony formation experiments. In this study, SiHa, CaSki and
HeLa cells were treated with or without Pep-7 at concentrations
indicated in Figure 3. However, only the growth of SiHa and
CaSki cells was inhibited by Pep-7. The differences in colony
number between the control (0 mM group) and the Pep-7-treated
group were significant (p,0.02) when the concentrations of Pep-7
increased up to 32 mM. The colony formation of HeLa cell was
not influenced by Pep-7 at concentrations of 16 through 160 mM
(p.0.1).
Pep-7 Induces Cell Cycle Arrest in Parallel with
Modulation of mRNA and Protein Levels
In this study, the cell cycle analysis revealed that the cell cycle
arrest induced by Pep-7 contributed much to the suppression of
cell proliferation. SiHa cells were treated with or without Pep-7
and then subjected to PI staining cell cycle analysis by flow
cytometry as described in Materials and Methods. As shown in
Figure 4 (A and B), Pep-7 inhibited G1-to-S phase transition of
SiHa cells significantly (p,0.02). The percentage of cells in
S-phase dropped from 25.96% (control) to 14.75% when treated
with 32 mM Pep-7, and to 8.75% when treated with 80 mM
Pep-7.
To address the exact mechanism of Pep-7-induced G1 arrest,
the expression of different proteins involved in regulating G1-to-S
transition was monitored by qRT-PCR and Western blot. Data
showed that treatment of SiHa and CaSki cells with 80 mM Pep-7
significantly reduced the expressions of Cyclins A, D1 and E1 at
both RNA and protein levels. On the other hand, pRb protein
level was increased but HPV16E7 protein was reduced by Pep-7,
though RNA levels of these genes were not affected by Pep-7
[Figure 4 (C and D)]. This suggests that the peptide may modulate
transcription of the cyclins while affecting the stability of
HPV16E7 and pRb protein.
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Measurements of pRb half-life were carried out. SiHa cells were
treated with or without Pep-7 for 24 h after seeded in 6-well plates
overnight, and then cycloheximides were added at a concentration
of 50 mg/ml, and cells were collected at different time points for
Western blot assay. A summary of three experiments is shown in
Figure 1. Competitive ELISA Assay. (A) Positive clones’ affinities to 16E7 were tested by competitive ELISA. HPV16 E7 protein was coated in
microtiter wells. Positive phage Clones 5 and 9 and negative control phage at concentrations of 10
13 cfu/ml to 10
5 cfu/ml, competed with HPV16E7
mAb, respectively, for binding the coated E7 protein. (B) The synthetic peptides were tested for affinities to 16E7. Pep-7 or N-pep at concentrations of
0.08 mM to 800 mM competed with HPV16 E7 mAb and HPV18 E7 anti-serum for binding to target. Data were presented as the mean 6 SE from three
independent experiments (
*,p ,0.02;
**,p ,0.01).
doi:10.1371/journal.pone.0017734.g001
Figure 2. Cell-uptaking and Intracellular Location of the Selected Peptide. SiHa cells were observed under a fluorescence microscope (A)
(scale bar: 50 mm) or analyzed by FCS (B) after 8 h or 24 h of incubation with 80 mM green fluorescent labeled F-pep.
doi:10.1371/journal.pone.0017734.g002
Antagonist Peptide Targeting HPV16 E7
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17734Figure 5D. pRb half-life was significantly expanded in Pep-7
treated groups, compared with control, supporting that Pep-7
induced pRb stabilization. In contrast, the phosphorylation of
pRb was not affected significantly by Pep-7 as shown in
Figure 5E.
Pep-7 Blocks Interaction Between pRb and HPV16E7 and
Reactivates pRb/E2F Pathway
The competitive ELISA test between positive clones and pRb
showed that the binding between positive clones and HPV16E7
could be disrupted by the pRb protein (Figure 5A). The inhibition
Figure 3. Effect of Pep-7 on Cell Proliferation. The effect of Pep-7 on cell growth at concentrations indicated were tested by MTT and
clonogenic assay. Cell viability was presented as a percentage of A540 relative to the control cells. MTT experiments (A to C) results are presented as
mean 6 SE of data obtained from at least two independent run in sextuplicate. (A) Pep-7 effect on CaSki cell growth; (B) Pep-7 effect on HeLa cell
growth; (C) comparing effect of 80 mM N-pep and Pep-7 on SiHa cell growth; (D) Photograph of cell clones stained with crystal violet; and (E) The
average 6 SE clone numbers of each group from three independent experiments (
*,p ,0.02;
**,p ,0.01).
doi:10.1371/journal.pone.0017734.g003
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17734Figure 4. Pep-7-Induced Cell Cycle Arrest and Relative Gene Expression. (A) Statistical data of cell phase distribution from three
experiments; (B) Representative images of flow cytometry, with (1) showing the results for the control, (2) showing the results for the 40 mM Pep-7
treatment, and (3), for the 80 mM Pep-7 treatment; (C) The RNA level of pRb, HPV16E7, and cyclins A, D1, and E1 in SiHa and CaSki cells treated with or
without 80 mM Pep-7; (D) The protein level of p107, p130 and the above genes in SiHa and CaSki cells treated without(Lane NC) or with 80 mM Pep-7
(Lane Pep-7). b-actin was used as loading control, and protein level was calculated from the band intensities of each proteins ralative to that of b-
actin. Results represent means 6 SE (
*,p ,0.02).
doi:10.1371/journal.pone.0017734.g004
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increased with an increase in pRb concentration. The results
suggest that the selected peptide might compete with pRb for
binding to HPV16E7.
To determine whether the peptide disrupts the binding of
HPV16E7 with pRb, the Pep-7 effect on the interaction between
pRb and HPV16E7 was evaluated. First, we performed His-pull
down assay. Results showed that His-HPV16E7 fusion protein
could not pull down pRb from 293T cell lysates with Pep-7
present. Without Pep-7 interference, however, pRb was pulled
down by His-HPV16E7 fusion protein (Figure 5B). In addition,
the Co-IP assay performed using Cos7 cells co-transfected with
HPV16E7 and pRb constructs yielded results similar to those of
the pull-down test. HPV16E7 could be immunoprecipitated by the
pRb antibodies without the presence of Pep-7, but when cells were
treated with Pep-7, HPV16E7 could not be immunoprecipitated
by the pRb antibodies (Figure 5C). These results indicated that
Pep-7 disrupted the binding between the HPV16E7 and pRb
proteins both in vitro and in vivo.
As pRb represses the transcription factor E2F, which regulates
the transcription of genes such as cyclin E, its release by Pep-7
from E7 may restore the down-regulation of transcriptional
activity of E2F. The speculation was verified by E2F-responsive
reporter assays. Reporter constructs with cyclin A, E1 and D1
promoters containing E2F binding sites were transfected into SiHa
and CaSki cells. The cells were treated with Pep-7 24 h post
Figure 5. Pep-7 Blocks Interaction Between pRb and HPV16E7 and Stabilizes pRb. (A) Competition between positive clones and pRb at
concentrations indicated for binding to HPV16 E7. (B) His-pull down experiment. Lane 1, 293T cell lysates tested by Western blot directly; Lane 2,
HPV16 E7 protein tested by Western blot directly; Lane 3, pRb pulled down by HPV16 E7-His-band resin from 293T cell lysates; Lane 4, pRb pulled
down by HPV16 E7-His-band resin from 293T cell lysates in the presence of Pep-7. (C), Co-IP of HPV16 E7 and pRb. Cos7 cells co-transfected with His-
pRb or YFP-HPV16E7 were treated with (lane 2) or without Pep-7 (lane 1 and 3). The cell lysates (left panel) or immunoprecipitates of pRb antibody
(right panel, lane 1 and 2) or Flag antibody (right panel, lane 3) were blotted with HPV16 E7 or pRb antibodies; (D) half-life study of pRb with or
without Pep-7 treatment. SiHa cells incubated with or without 80 mM Pep-7 were treated with 50 mg/ml cycloheximide for 12 h, and the cells were
harvested for Western blotting at time points indicated; (E) phosphorylation of pRb assay in cells treated with or without Pep-7. SiHa cells were
harvested and subjected to Western blotting probed with pRb and Phospho-Rb antibodies respectively, post 24 h incubation with or without 80 mM
Pep-7. b-actin was used as loading control, and protein level was calculated from the band intensities of each proteins relative to that of b-actin
(
*,p ,0.02;
**,p ,0.01).
doi:10.1371/journal.pone.0017734.g005
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Figure 6A, Pep-7 resulted in remarkable down-regulation of
activities of cyclin A, E1 and D1 promoters. On the other hand,
when the E2F binding sites in cyclin A and E1 promoters were
mutated, the down-regulations of the promoters by Pep-7 were
abolished. Figure 6C shows that the activities of mutated promoter
constructs, pMCCNA-Luc and pMCCNE1-Luc in SiHa cells
treated with Pep-7 have negligible differences from those in
control groups.
In order to further determine the involvement of pRb-E2F
pathway in Pep-7 function, members of Rb family including pRb,
p130 and p107 were knocked-down by siRNA to evaluate the
effect of their deficiency on Pep-7 function. SiHa cells were co-
transfected with E2F-responsive luciferase reporter plasmids and
siRNA of Rb, p130 and p107, respectively. The cells were then
treated with or without Pep-7 at 24 h post transfection for another
24 h before subjected to luciferase activities evaluation. Results in
Figure 6B indicated that inhibition of pRb also abrogated the
suppression of cyclin A, E1 and D1 promoter activities by Pep-7,
whereas knocking down p130 or p107 did not affect the influence
of Pep-7 on these promoters. This confirmed that pRb but not
p130 or p107, was involved in activity repression of E2F by Pep-7.
Pep-7 Inhibits Tumor Growth in Animal Model
The anti-tumor efficacy of the selected peptide was further
investigated in vivo; a subcutaneous tumor was constructed in nude
mice by inoculation with 1.5610
7 SiHa cells. The mice were then
treated for 16 days with intravenous injections of PBS or Pep-7 at
doses of 400 mg/mouse and 800 mg/mouse, respectively. In the
experiment, Pep-7 therapy showed significant anti-tumor efficacy
(p,0.01, Figure 7). At the end of the experiment, the tumor
growth was inhibited by 77.92% in 400 mg Pep-7/mouse dose
group and 93.86% in 800 mg Pep-7/mouse dose group, respec-
tively, compared with that in the control (PBS) group (Figure 7B).
The H/E staining and BrdU uptake test of the tumor tissues also
revealed that Pep-7 repressed tumor growth (Figure 7, C and D).
In addition, immunohistochemical results showed that pRb
protein level increased but HPV16E7 decreased in the Pep-7-
Figure 6. Luciferase Reporter Assay. The luciferase reporter activity of each sample was normalized against the corresponding protein content
prior to calculation of the fold induction value relative to the controls. (A) Luciferase activity of E2F-dependent-promoters; (B) Comparison of the
luciferase activity of E2F-dependent promoters with pRb, p107, p130, or negative control siRNA treatment; (C) Luciferase activity of mutant promoters
(E2F binding sites mutated). Results represent means 6 SE from three experiments (
*,p ,0.02;
**,p ,0.01).
doi:10.1371/journal.pone.0017734.g006
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and C). Tissues from the 800 mg dose group were not examined
due to the fact that the tumors were too small for the preparation
of sections. Furthermore, qRT-PCR indicated that Pep-7 also
reduced cyclins A, D1, and E1 expression at the RNA levels
(Figure 8A). The in vivo results were consistent with the results
in cell experiments, indicating that the Pep-7 inhibits tumor
growth in animals through the same mechanism as in HPV-
positive cells.
Discussion
Current therapeutic strategies for HPV-associated tumors
include surgical removal of the lesion, radiotherapy plus
cisplatin-based chemotherapy, and non-specific stimulation of
innate immunity. But the most commonly used cytotoxic therapy,
cisplatin-based combination chemotherapy, has produced re-
sponse rates ranging from 20% to 30% and overall survival of
less than 10 months [27,28,29,30]. Recently developed prophy-
lactic HPV vaccines hold great promise for the prevention of
HPV-associated cancers in the future [31]. However, prophylactic
HPV vaccines do not have therapeutic effects against pre-existing
HPV infections and HPV-associated lesions. Furthermore, due to
the considerable burden of HPV infections worldwide, and the
limitation of prophylactic HPV vaccine application by high costs
and medical infrastructure problems [32], it would take decades
for preventive vaccines to lower the prevalence of cervical cancer.
In fact, the incidence of cervical cancer is estimated to increase by
over 40% by the year 2020 [33]. Thus, novel treatment strategies
are urgently required.
With the aim of obtaining reagents that could be utilized in
HPV-associated tumor therapy, an antagonist peptide against
HPV16E7 was isolated from a phage display library. Competitive
ELISA assay revealed that the selected peptide Pep-7 bound to
HPV16E7 protein with high specificity and affinity in vitro. This
specific binding was peptide sequence-dependent because the
negative peptide N-pep showed no affinity for HPV16E7 in the
same experiment.
Figure 7. The anti-tumor efficacy of Pep-7 in vivo. Mice bearing subcutaneous tumors were treated for 16 days with intravenous injections of
PBS (control) or Pep-7 at doses indicated every other days. Results represent means 6 SE. (A) Tumor growth curve. Tumor volume was calculated
using the formula ‘‘volume=length6width
2/2,’’ (B) Tumor growth inhibition ratio, represented as relative tumor weight to control. Relative tumor
weight (% of control)=average tumor weight of each dose treatment group/average tumor weight of control group’’; (C) H/E staining and BrdU-
incorporation staining of tumor tissues. (1) H/E staining of section from PBS treatment group; (2) H/E staining of tumor tissue from 400 mg Pep-7
treatment group; (3) BrdU antibody staining of section from mouse up-taking BrdU in PBS treatment group; (4) BrdU antibody staining of section
from mouse up-taking BrdU in 400 mg Pep-7 treatment group; (5) BrdU antibody staining of section from mouse without up-taking BrdU in PBS
treatment group (6) PBS staining of section from mouse up-taking BrdU in PBS treatment group; (D) statistical data of the BrdU-positive cells by
accounting for 1000 total cells in each case (
*,p ,0.02;
**,p ,0.01; Original magnification, 2006).
doi:10.1371/journal.pone.0017734.g007
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MTT assay indicated that it significantly inhibited the viability of
HPV16-positive cervical cancer cells. This inhibition was specific
and dose-dependent. In fact, no significant anti-proliferative effect
was observed either in HPV16-positive cells treated with the
negative control peptide N-pep, or in HPV16-negative cells
treated with Pep-7 [Figure 3 (A–C)]. As shown in Figure 3 (D and
E), this specific inhibition was further confirmed by the colony
formation assay, which indicated significant, dose-dependent Pep-
7-blocked clone formation in SiHa and CaSki cells, but not in
HeLa cells. This was in line with the competitive ELISA results,
which showed that Pep-7 bound to HPV16E7 but not to
HPV18E7 protein. Therefore, the inhibition of cell proliferation
observed in SiHa cells and CaSki cells may be ascribed to
HPV16E7 impairment by Pep-7. Moreover, the anti-tumor
efficacy of Pep-7 was further determined in mammals. The
therapeutic results were encouraging. The selected peptide showed
significant anti-tumor efficacy on SiHa tumor xenografts (Figure 7),
implying a potent anti-tumor perspective in vivo for HPV16-related
neoplasms.
Suppression of cell proliferation may be the result of cell cycle
arrest or apoptosis. It is well verified that the main function of
HPV16E7 is inactivating retinoblastoma family of proteins pRb
[22,24] and leading to cell cycle disorder. Therefore, we focused
our investigation on Pep-7’s effect on cell cycle in the current
study. Previous studies have indicated that HPV E7 protein
prevents G1 arrest and drives cells from the G1 to the S phase in
the cell cycle [34,35]. In our study, the flow cytometry assay
indicated that Pep-7 induced G1 arrest in SiHa cells [Figure 4 (A
and B)], consistent with the cell proliferation inhibition results,
arguing for that Pep-7 induces G1 arrest by eliminating the
functions of HPV16E7. In addition, competitive ELISA assay
showed that the selected phage clones competed with pRb for
binding to HPV16E7 (Figure 5A). Pull down experiments and Co-
Figure 8. Gene Expression in Tumor Tissues. (A) Relative RNA levels of tumor tissues from qRT-PCR. (B) Immunohistochemical staining of pRB
expression. panel 1, tumor tissue from control group; panel 2, tumor tissue from 400 mg Pep-7 treatment group; (C) Immunohistochemical staining of
HPV16 E7 expression. panel 1, tumor tissue from control group; panel 2, tumor tissue from 400 mg Pep-7 treatment group (
*,p ,0.02;
**,p ,0.01;
Original magnification, 2006).
doi:10.1371/journal.pone.0017734.g008
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association between HPV16E7 and pRb proteins [Figure 5 (B and
C)]. It is reported that one mechanism of the inactivation of pRb
by E7 is the targeted destabilization of pRb [11,12,36,37,38]. In
agreement with these reports, our results demonstrated that Pep-7
could reduce the E7 protein level while inducing pRb protein
augmentation in HPV16-positive cells. In contrast, Pep-7 did not
exhibit an effect on the protein levels of other two members of pRb
family, p107 and p130 (Figure 4). One explanation for this may be
that E7 differentially regulates pRb, p130 and p107 [39]. Pep-7
abolishes the effect of E7 on pRb, whereas its interactions with
p130 and p107 are not disturbed. We also found that Pep-7
treatment had no significant influence on the RNA levels of
HPV16E7 and pRb. Furthermore, the stabilization of pRb with
Pep-7 was addressed by half-life study. In this experiment, pRb
half-life was expanded significantly by Pep-7, compared with
control (Figure 5D). Therefore, it is reasonable to speculate that
Pep-7 may rescue the tumor-suppressing function of pRb by
releasing it from the HPV E7/pRB complex and preventing its
degradation induced by HPV E7.
HPV E7/pRB association abrogates the transcriptional repres-
sor activity of pRB/E2F complexes, resulting in the dysregulated
expression of E2F target genes [17]. On the basis of these
concepts and our results mentioned above, it seems possible to
ascribe Pep-7 function to the restoration of pRb/E2F pathway
and the inhibition of E2F dependent genes. In order to confirm
this speculation, a series of gene expression tests were performed.
First, results of the qRT-PCR assay indicated that Pep-7
treatment led to a decline in the RNA levels of cyclins A, D1,
and E1. Next, Western blot results confirmed the expression
reduction induced by Pep-7 (Figure. 4). Finally, the luciferase
reporter experiment verified that Pep-7 inhibited E2F transcrip-
tional activity. Pep-7 treatment resulted clearly in activitiy down-
regulation of cyclin A, E1 and D1 promoters, whereas this
suppression was abolished after the E2F-binding sites were
mutated in promoters of cyclin A and cyclin E1 (Figure 6C).
Like the E2F-binding sites mutation, knocking down pRb by
siRNA abolished the effect of Pep-7 on these E2F response
promoters, whereas the selected peptide-mediated inhibition of
the above promoter activities did not changed with the p107 and
p130 knocked-down (Figure 6B). As the efficiencies of knocking
down pRb, p107 and p130 are similar to be about 80%, the
different influences on Pep-7 function may be due to the fact that
p107 and p130 are not involved in the Pep-7 functional
mechanism, which is consistent with the Western blot results that
Pep-7 had negligible impact on p107 and p130 protein. Although
p130 and p107 may be involved in regulating the activities of
members of E2F family, this difference is still reasonable as studies
have indicated differences in the interactions of the pRb, p107
and p130 with the members of the E2F family [40,41,42]. In
conclusion, these results support our hypothesis that the selected
peptide Pep-7 demolishes the function of HPV16 E7 protein by
inducing its degradation, disrupting its association with pRb, and
preventing pRb degradation, which restores the pRb/E2F
pathway and suppresses cell proliferation consequently.
Moreover, identical conclusion could be drawn out from animal
experiments. In agreement with results in cell lines, Pep-7 showed
significant anti-tumor efficacy on SiHa tumor xenografts (Figure 7).
BrdU incorporation and Immunohistochemistry assay revealed
that similar to that in HPV16-positive cells lines, Pep-7 induced
cell growth repression, E7 protein decline, as well as pRb protein
accumulation in tumor tissues (Figure 7 and Figure 8). qRT-PCR
indicated that Pep-7 also reduced cyclins A, D1, and E1
expression. These results indicate that Pep-7 inhibits tumor
growth in animals through the mechanism similar to that in
HPV16-positive cells.
Previous studies have revealed that LXCXE of HPV E7 binds
entirely through the B pocket domain of pRb [43]. For high risk
HPV, the LXCXE motif is also required for pRb degradation
[44], while the zinc-binding region of the carboxyl-terminal
domain of E7 is important for its dimerization and intracellular
stabilization [43,45]. In this study the Pep-7 has the amino acids
sequence SACPKGLDWCGG (C&C bridged). We did not find
any similarity of this to the sequences of B pocket domain of pRb.
This argued that Pep-7 may not interfere with E7/pRb interaction
through binding site competition. Considering the results that the
peptide could also compete with E7 antibodies for binding to E7
protein in vitro, and induce intracellular degradation of E7, we
presume that its association with E7 changed the protein’s
structure which was critical for its function and intracellular
stability. However, the precise mechanisms by which Pep-7
interacts with E7 and releases pRb from E7/pRb complex remain
to be elucidated.
In summary, we have explored the possibility of developing new
therapeutics for cervical cancer by selecting peptides that bind
with high affinity and specificity to the E7 oncoprotein of HPV16.
Our study indicates that the selected peptide Pep-7 has anti-tumor
efficacy both in vitro and in vivo. The mechanism studies reveal that
the anti-tumor effect of Pep-7 is due mainly to its destruction of
HPV16E7 protein function by inducing its degradation and
disrupting its interaction with pRb, thus reactivating the pRb/E2F
pathway. In light of our results, this study may open new
perspectives in the treatment of HPV16-positive cancer.
Materials and Methods
Cell lines
HPV16-positive SiHa and CaSki cervical carcinoma cells were
supplied by China Center for Type Culture Collection (CCTCC).
The following cell lines used in this project were from our
laboratory: HPV18-positive HeLa cervical carcinoma cells, CNE
nasopharyngeal carcinoma cells, HaCat human keratinocyte cells,
COS7 (African green monkey SV40-transformed kidney fibroblast
cell line), 293T (human kidney epithelial cells), and NIH/3T3
mouse embryonic fibroblast cells. All cells were maintained in a
humidified atmosphere of 5% CO2, Dulbecco’s modified Eagle’s
medium (DMEM, pH 7.2), supplemented with 10% fetal calf
serum (FCS).
Antibodies and Reagents
Mouse anti-HPV16E7, mouse anti-p107 (SD107), mouse anti-
cyclin E1, mouse anti-cyclin A1 and mouse anti-cyclin D1
monoclonal antibodies were supplied by Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA). Rabbit monoclonal to pRb
antibody was supplied by Abcam Ltd. (Hong Kong, P.R. China).
Mouse monoclonal to p130/Rb2 antibody was supplied from
NeoMarkers For Lab Vision Corporation (Fremont, CA, USA).
pRb Antibody Sampler Kit, including Phospho-pRb (Ser780),
Phospho-pRb (Ser795) and Phospho-pRb (Ser807/811) antibodies
and pRb (4H1) Mouse antibody, was supplied by Cell Signaling
Technology, Inc. (Danvers, MA, USA). HRP-coupled mouse anti-
M13 antibody, HRP-conjugated goat anti-mouse IgG and HRP-
conjugated goat anti-rabbit IgG were supplied by Amersham
Biosciences (Piscataway, NJ, USA) and KPL (Gaithersbug, MD,
USA), respectively. Mouse anti-HPV18E7 serum was prepared in
our laboratory. TMB substrate kit was obtained from eBioscience
Inc. (San Diego, CA, USA). Ni-NTA agarose beads (His-band
Resin) and protein G agarose beads were supplied by Amersham
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TM phage
display peptide library kit was purchased from New England
Biolabs Inc. (Cambridge, MA, USA). DMEM, trypsin, and
TRIzol reagent were supplied by Invitrogen (Carlsbad, CA,
USA). Fetal calf serums (FCS) were purchased from Sijiqing
(Hangzhou, P.R. China). 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphe-
nyl tetrazolium bromide) (MTT) and dimethylsulfoxide (DMSO)
were supplied by Sigma Chemical Co., (Aaint Louis, MI, USA). 5-
Bromo-29-deoxyuridine(BrdU) and Monoclonal Anti-BrdU anti-
body produced in mouse were bought from Sigma-Aldrich, Inc.
(Aaint Louis, MO, USA). Other chemicals were of analytical grade
and obtained from local commercial resources.
Plasmids and Reporter Constructs
The primers used in plasmid constructs of this study are listed in
Table 1. HPV16E7-pEYFP plasmid was constructed by sub-
cloning the HPV16E7 gene into the EcoRI and BamHI sites of
pEYFP-N1. The HPV16E7 gene was obtained by PCR from
HPV16E7- pET28a (+) plasmid, which was maintained by our
laboratory, using primers pE7N1f and pE7N1b. The pRb gene
was obtained by nest PCR from HeLa cDNA using pRb1, pRb2,
pRb3, pRb4 as primers. The PCR product was then inserted into
the HindIII and Xho I sites of pcDNA3.1-His/V5-Topo. pA3-Luc-
Cyclin D1 luciferase reporter plasmid containing the cyclin D1
promoter sequence 21745 to +134 was maintained by our
laboratory. Both pCCNE1-Luc and pCCNA1-Luc were con-
structed by nest PCR to amplify fragments of cyclins E1 and A
promoter sequences (cyclin E1: +3t o+594; cyclin A: 2284 to
+254) which include E2F binding sites [46,47] from HeLa cDNA,
respectively. Primers used in pCCNE1-Luc construction were
P(CCE1), P(CCE2), P(CCE3), and P(CCE4), while primers
P(CCA1), P(CCA2), P(CCA3), and P(CCA4) were used in
PCCNA1-Luc construction. The PCR products were then cloned
into the Kpn1 and Bgl II sites of the pGL3-enhancer (Promega,
Madison, WI, USA) luciferase reporter plasmid. The double
mutants of E2F sites in the pCCNE1, which changed
TGTCCCGC at position +7 to TGTCATGC and changed
GCGCGCAA at position +497 to GCGATCAA, were performed
by site-directed mutagenesis using the megaprimer-PCR method
as described previously [48]. Luciferase reporter plasmid
pMCCNE1-Luc, was made by sub-cloning of the corresponding
PCR fragments into pGL3-enhancer, respectively. Primers
P(pGL31),P(CCME1), P(CCE3), P(CCE4) and P(CCME2) were
used in the megaprimer-PCR processes. The E2F binding sites
muted cyclin A promoter luciferase reporter plasmid, pMCCNA1-
Luc, in which the E2F binding sites TTTGGCTC at position +31
and TTTGGGCG at position +165 were changed into
TTTGATTC and TTTGGATG, respectively, was generated
form pCCNA1-Luc as above, using P(pGL31), P(CCMA1),
P(CCA3), P(CCA4), and P(CCMA2) as primers. The mutations
were confirmed with DNA sequencing by Shanghai Sangon
Biological Engineering Technology and Service Co., Ltd.
(Shanghai, P.R. China).
Protein Expression and Purification
The HPV16 E7 gene was amplified by PCR and cloned into the
BamHI/EcoRI sites of the pET28a (+) vector (maintained by our
lab). The pET28a (+)-HPV16E7 clone was then transformed into
Escherichia coli BL21. Expression of His-E7 was induced by
1 mmol/L IPTG; the protein was extracted in denaturing
conditions according to the Qiagen protocol and its purification
carried out by immobilized-metal affinity chromatography with
Ni-NTA agarose beads following the manufacturer’s instructions
(Amersham Biosciences, Little Chalfont, UK).
Phage Display Screening
HPV16E7 protein [100 mg/ml in 0.1 M NaHCO3 (pH 8.6) with
5 mg/ml BSA] was immobilized in 96-well microtiter plates
(Corning,NY,USA)andincubatedovernight at4uC.Thefollowing
day, the wells were blocked by incubation for 2 h at 37uC with 3%
BSA and rinsed five times with TBST [Tris?Cl (pH 7.5) 50 mmol/
L, NaCl 150 mmol/L, and 0.1% Tween 20]. The plates were
subjected to panning for 1 h at room temperature with the phage
particles, followed by washing three times for 15 min with TBS
[Tris?Cl (pH 7.5)50 mmol/L, NaCl 150 mmol/L].Thereafter, the
bound phages were eluted for 1 h at room temperature with 1 mg/
ml HPV16E7 protein in 0.2 M Glycine-HCl (pH 2.2), followed by
neutralization with 1.0 M Tris-HCl (pH 9.1). The recovered
phages were amplified in Luria-Bertani plates containing stationary
phase ER2537 cells. Amplified phages were screened in additional
rounds and then plated to obtain isolated clones.
To characterize the individual clones’ binding to HPV16E7,
plaques were picked at random, amplified, and tested for
HPV16E7 binding ability by ELISA using HRP conjugated
anti-M13 antibody (Amersham Biosciences, Piscataway, NJ, USA),
followed by TMB substrate coloration (eBioscience, San Diego,
CA, USA) for colorimetric evaluation. The absorbance value was
measured at 450 nm (A450) on a microplate reader. The PBS was
immobilized to the plates as negative control. The clone was
Table 1. Primer sequences used in plasmid constructs.
Name Primer Sequence (59-39) Name Primer Sequence (59-39)
pE7N1f CGGAATTCCCACCATGCAT GGAGAT ACA CCT ACA P(CCE1) ACCCAGGCTGGTCTCGAAC
pE7N1b CGGGATCCCGTGGTTTCTG AGA ACA GAT GG P(CCE2) TTCGCATCCCTGTGGACC
pRb1 TGTAACGGGAGTCGGGAGAG P(CCE3) GTGGGTACCGCTGGGATTAAAGGCGTGAG
pRb2 TGTCCACCAAGGTCCTGAGATC P(CCE4) CGTAGATCTGATGGGGCTGCTCCGG
pRb3 CCGAAGCTTGCCACCATGCCGCCCAAAACC P(CCAM1) CTACGACTATTCTTTGGATGGGTCGGTGCG
pRb4 CCGCTCGAGCGTTTCTCTTCCTTGTTTGAGG P(CCAM2) TCTGGGCGTCTTTGATTCGCCACGCTG
P(CCA1) AGCCAGGAAATAAGAAGAGC P(pgl31) CCAACAGTACCGGAATGC
P(CCA2) CGTCTGCTGCAATGCTAG P(CCEM3) CCGCCCGCGATCAAAGGGGGAAGG
P(CCA3) CAGGGATCCCACTGCTCCCGGGAGTGG P(CCEM4) GGTGGTACCTAAATGTCATGCTCTGAGCCGGG
P(CCA4) GTGGGTACCGCTTAGAGTCAGCCTTCGGACAG
doi:10.1371/journal.pone.0017734.t001
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times higher than that of the negative control well.
Analysis of Amino Acid in Phage Clones and Peptide
Synthesis
The nucleotide sequences coding for random peptides displayed
on the positive-phage coat proteins were determined by Shanghai
Sangon Biological Engineering Technology and Service Co., Ltd.
(Shanghai, P.R. China). The corresponding peptides were
chemically synthesized with or without an N-terminal fluorescein
label (Chinese Peptide Company, Hanzhou, P.R. China) for
further study. The peptide with the same amount of amino acid,
but having random sequences, was synthesized as a negative
control peptide. Crude peptides were purified by HPLC and
checked by mass spectrometry. Except otherwise noted, peptides
were dissolved in DMSO to obtain 10 mmol/L solutions,
supplemented with equimolar DTT, and stored at 220uC.
Competitive ELISA Assay
The specificity and affinity of the positive clones and synthetic
peptides were determined by competitive ELISA. 400 ng/well
HPV16 E7 protein was coated overnight in microtiter wells at
4uC. The positive clones or peptides at different concentrations
mixed with HPV16E7 mAb were incubated with the coated E7
protein in microtiter wells for 3 h. The mixture at the same
concentration of the library phage and HPV16E7 mAb was set as
negative control. The reaction was revealed by incubation with the
HRP-conjugated goat anti-mouse antibody (KPL, Gaithrsbug,
MD, USA) as described above. HPV16E7 mAb alone at the same
concentration, incubated with the coated E7 protein, gave
benchmark absorption. The inhibitory ratio was calculated by
the following formula: Inhibitory ratio=100%2(A450 of mixture
well/A450 of mAb alone well)6100%.
Peptide Internalization and Visualization
The 5-FAM labeled peptides were used to monitor the cell
uptake and intracellular location of the peptide. SiHa cells were
seeded on the coverslips in 12-well plates (1610
5/well) and
cultured overnight. The DMEM was replaced with a fresh
medium, supplemented with 80 mM 5-FAM labeled peptide. Cells
were washed three times with a PBS buffer after 8 h and 24 h of
incubation, respectively, and then observed under a fluorescence
microscope Leica DMI 6000B. Images were captured with Leica
AF6500 software (Leica Mikrosysteme Vertrieb GmbH, Wetzlar,
Germany). The percentage of cells up-taking F-pep was analyzed
by flow cytometry sorting.
Cell Viability Assay
Cell viability was determined with an MTT assay. Briefly, the
cells were seeded into 96-well plates at a density of 4–5610
3 cells/
well. The cells were allowed to recover for 24 h before the medium
was replaced with DMEM supplemented with peptides at different
concentrations. The solvent of the peptides was set as the control.
The peptide-supplemented medium was replaced daily and the
respective concentrations were maintained. The cells were
subjected to an MTT cell proliferation assay at different time
points. The plates were incubated at 37uC for 3 h with the
addition of 20 ml/well MTT (5 mg/ml). Untransformed MTT in
the solution was removed by aspiration. The formazan product
was dissolved in DMSO, and plates were shaken vigorously at
room temperature for 10–15 min to ensure complete solubiliza-
tion. The optical density of the formazan solutions was measured
by microplate reader at 540 nm.
Clonogenic Assay
Cells were seeded in DMEM at 1610
3 cells/well density in 12-
well plates and allowed to attach to the substrate overnight.
Thereafter, cells were treated with 0 mM, 16 mM, 32 mM, 80 mM,
and 160 mM peptide in DMEM, and the medium was changed
every three days. The plates were observed daily for colony
formation. After 8 (for HeLa cells) or 14 (for SiHa and CaSki cells)
days of treatment, the cultures were washed three times with PBS
and stained with crystal violet in ethanol for 15 min. The colonies
were then counted and photographed with the AlphalmagerH EP
image acquisition system (Alpha Innotech, Santa Clara, CA,
USA).
Flow Cytometry
Cell cycle distribution was determined by flow cytometry DNA
analysis. SiHa cells (2610
5/well) were allowed to attach to the
substrate overnight and then treated with or without 32 mM and
80 mM Pep-7 in full-culture medium. After 24 h, cells were
harvested and counterstained with PI (Invitrogen, Carlsbad, CA,
USA) for flow cytometry according to the manufacturer’s
instructions. Briefly, cells were trypsinized and resuspended in
1 ml PBS. Cell suspension was dropped slowly into 4 ml
anhydrous ethanol pre-cooled at 220uC and mixed. After
standing at 220uC for more than 15 min, the ethanol was
removed by centrifugation, after which 5 ml PBS was added and
mixed, and cells were re-hydrated at room temperature for
15 min. PBS was then removed by centrifugation. Cells were
stained with 2 mg/ml propidium iodide in 1 ml dilution buffer
(100 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 1 mmol/L
CaCl2, 0.5 mmol/L MgCl2, 0.1% Nonidet P-40, 100 mg/ml
RNAase) at room temperature for 15 min and subjected to flow
cytometry analysis. Analysis was performed on an Epics-XL flow
cytometer (Beckman Coulter, Inc. CA, USA) with Modfit 3.0
software (Verity Software House, Topsham, ME, USA).
Western Blot
Western blotting was carried out as described previously
[49,50]. The cells were seeded into 6-well plates, allowed to
attach to the substrate overnight, and then treated with or without
80 mM Pep-7. After another 48 h of treatment, the cells were lysed
in lysis buffer (Beyotime Institute of Biotechnology, Jiangshu,
China) containing PMSF (Sigma Chemical Co., St. Louis, MI,
USA) for 30 min at 4uC. The lysate was then centrifuged for
20 min at 13,000 rpm and 4uC. The proteins were then separated
through SDS-PAGE and transferred onto the PVDF membrane
(ImmobionH-P Transfer Membrane, Millipore Corp., Billerica,
MA, USA). Membranes were blocked in a Tris-buffered saline
with 0.1% Tween-20 (TBS-T) solution with 5% nonfat dry milk
and incubated overnight with primary antibodies at 4uC. The
immunoreactive signals were detected by HRP-conjugated
secondary antibodies (KPL, Gaithersburg, MD, USA) followed
by SuperSignalH West Pico Chemiluminescent Substrate (Thermo
Scientific, Milford, MA, USA.). Anti-b-actin antibodies were used
to control protein loading. For the in vivo studies, tumors were
harvested, and the cell lysates were prepared and transferred to a
clean Eppendorf tube and centrifuged for 30 min at 14,000 rpm.
The supernate was probed by western blotting, as described above.
For pull-down analysis, the purified His-HPV E7 protein
(200 mg/ml650 ml) was preincubated with 100 ml His-band Resin
(Amersham Biosciences, Little Chalfont, UK) for 4 h at 4uC. The
beads were then washed four times with lysis buffer and divided
into two equal portions. One half was added with the supernate of
the 293T cell lysate with 300 mg total proteins and 10 ml (8 mmol/
L) Pep-7, while an equal amount of cell lysate supernate and 10 ml
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incubated overnight at 4uC under continuous agitation. Beads
were subsequently washed four times with a lysis buffer. Bound
proteins were eluted by boiling in Laemmli sample buffer and
analyzed by Western blot.
For Co-IP, Cos-7 cells seeded in 100 mm plates were co-
transfected with HPV16E7-pEYFP-N1 and pRb-pcDNA3.1 using
the PEI reagent (Sigma-aldich Chemie GmbH, Steinheim,
Germany) described previously [51]. Cells were treated with or
without 80 mM Pep-7 24 h post-transfection, and lysed for 30 min
in lysis buffer 48 h post-transfection. Lysate supernate prepared as
above were incubated with 10 ml rabbit anti-pRb antibody or
mouse anti-flag (negative control) antibody and washed protein G
agarose beads (Amersham Biosciences, Little Chalfont, UK)
overnight at 4uC under continuous agitation. Beads were
subsequently washed four times with the lysis buffer. Bound
proteins were eluted by boiling in a Laemmli sample buffer and
subjected to western blot assay.
Half-life measurement
SiHa cells seeded in 6-well plates were treated without or with
80 mM Pep-7 for 24 h. The cells were then treated with 50 mg/
ml cycloheximide for 0 to 12 h. The cell lysates collected at
different time points were subjected to Western blotting assay as
above. Band intensity was used to determine the proteins half-life
[52].
siRNA Synthesis and Cell Transfection
The siRNAs were synthesized by Shanghai Gene Pharma Co.,
Ltd. (Shanghai, P.R. China), as follows, E7 siRNA (target
sequence: GCTTCGGTTGTGCGT) [53], sense: 59-GCUUCG-
GUUGUGCGUACAA dTdT-39, antisense: 59-UUGUACGCA-
CAACCGAAGC dTdT-39, pRb-1, target sequence: 59-AAG-
TTTCATCTGTGGATGGAG-39; pRb- 2, target sequence: 59-
AATGGTTCACCTCGAACACCC-39; p107-1, sense: 59-GCC-
GGUUACAGAGUAUUGUTT-39; antisense: 59-ACAAUACU-
CUGUAACCGGCTT-39; p107-2, sense: 59-GCCCUUCUAA-
GAGUUUGAATT-39; antisense: 59-UUCAAACUCUUAGAA-
GGGCTT-39; p130-1, sense: 59-GGACUUAGUUUAUGGA-
AAUTT-39; antisense: 59-AUUUCCAUAAACUAAGUCCTT-
39; p130-2, sense: 59-GCCCUUCUAAGAGUUUGAATT-39;
antisense: 59-AUUCUCAACAAAUAGCCGCTT-39; negative
control sense: 59-UUCUCCGAACGUGUCACGUTT-39, anti-
sense: 59-ACGUGACACGUUCGGAGAATT-39 [54].
The cells were seeded in 12-well plate at a density of 3610
5
cells/well. The following day, cells were transfected with SiRNA
and luciferase reporter plasmids or siRNA alone, respectively,
using LipofectAMINE 2000 as described in the manufacturer’s
protocol (Invitrogen, Carlsbad, CA, USA).
Luciferase Gene Reporter Assay
The reporter assays were performed using Bright-Glo
TM
Luciferase Assay System (Promega, Madison, WI, USA) according
to the manufacturer’s instructions. Briefly, cells were plated in 12-
well plates at a density of 1.5610
5 cells/well. The following day,
cells were transfected with reporter constructs. After 24 h, cells
were pre-treated with or without 80 mM Pep-7 for another 24 h.
Thereafter, cell lysates were collected for reporter assays. The
luciferase reporter activity of each sample was normalized against
the corresponding protein content prior to calculation of the fold
induction value relative to the controls. Each sample was
determined in triplicate. The results represent means 6 SE from
three experiment runs.
RNA Extraction and qRT–PCR
Total RNA was extracted from the cultured cells using TRIzol
reagent (Invitrogen, Carlsbad, CA,USA) according to the
manufacturer’s instructions. qRT-PCR was used to confirm the
expression levels of mRNAs. Reverse transcription and qPCR
were performed according to the protocol of Reverse Transcrip-
tase System
TM and SYBRH premix Ex Taq
TM (Perfect Real Time)
(TaKaRa, Dalian, P.R. China) on the ABI 7300 Real Time PCR
System (Applied Biosystems, Foster City, CA, USA) supplied with
analytical software. b-actin mRNA levels were used for normal-
ization. Each sample was determined in triplicate. The results
represent means 6 SE from three experiment runs. The primers
used for real-time PCR [55] are listed in Table 2.
Mice Maintenance and Subcutaneous Tumor Model
Female Balb/C-nu/nu mice were supplied by the Medical
Experimental Animal Center of Guangdong Province (Guang-
dong, P.R. China). The care and use of laboratory animals have
been approved by the Tsinghua University Animal Care and Use
Committee, complying with the rules of REGULATIONS FOR
THE ADMINISTRATION OF AFFAIRS CONCERNING EX-PERI-
MENTAL ANIMALS (Approved by the State Council of P.R.
China)
A subcutaneous tumor model of nude mice was constructed. In
brief, six-week-old female nude mice (1862 g) were subcutane-
ously inoculated with 1.5610
7 SiHa cells. When the tumor size
reached about 100 mm
2, the mice were randomly divided into
four groups with 5 mice each, namely, control group, low-dose
group, middle-dose group, and high-dose group. The groups were
treated once every other day for 16 days, with intravenous
injections of PBS or Pep-7 at doses of 400 mg/mouse and 800 mg/
mouse, respectively. The mice were raised for another 3 weeks.
Tumor sizes were measured with a caliper every three days and
tumor volume was calculated using ‘‘volume=length6width
2/2.’’
At the end of the experiment, all mice were sacrificed and the
weights of the detached tumors were measured. Tumor growth
inhibition ratio was represented as the tumor weight relative to the
control, calculated using the formula, ‘‘Relative tumor weight (%
of control)=average tumor weight of treatment group/average
tumor weight of control group6100%.’’
Immunohistochemistry and H/E Staining
Three or two mice bearing tumor of each group were
prelabeled with intra-peritoneal injection of BrdU (100 mg/kg,
Sigma-Aldrich, Inc., Aaint Louis, MO, USA) 15 hours before
sacrificed. Tumor specimens were then prepared as formalin-
fixed, paraffin-embedded sections for hematoxylin-eosin staining,
BrdU and pRb immunohistochemical staining as previously
described [56,57]. In brief, immunostaining was performed on
formalin-fixed, paraffin-embedded sections using the anti-pRb
monoclonal and anti- BrdU monoclonal antibodies, respectively.
Before the application of the primary antibodies, an antigen
retrieval technique was performed. For pRb assay, the depar-
affinized and rehydrated slides were placed in 10 mmol/L citrate
buffer (pH 6.0) and heated in a microwave oven for 15 min at 700
W. H2O2 was used to inhibit endogenous alkaline phosphatase.
For BrdU incorporation test, sections were pretreated for 20 min
with 0.1% trypsin in PBS at 37uC following the 30 min incubation
in 2 N HCl at 37uC for DNA denaturation. After blocked, the
slides were then incubated with anti-pRb or anti-BrdU monoclo-
nal antibodies overnight at 4uC under dilutions of 1:100 and
1:500, respectively. The antibodies were detected by means of the
Strept Avidin-Biotin Complex (SABC) method (Wuhan Boster
Biological Technology, Ltd., Wuhan, P.R. China.) according to
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under a Nikon ECLIPSE TE2000-U microscope (Nikon Corpo-
ration, Tokyo, Japan) and images were collected and analyzed
with Pixera Penguin 600CL DiRactor
TM (Pixera Corporation, Los
Gatos, CA, USA). BrdU or pRb-positive cells were counted in
each section. The total cell number was determined by nuclear
staining with hematoxylin. At least 1000 total cells for each case
were counted.
Statistics and Data Analysis
All cell culture-based experiments were repeated at least three
times unless otherwise indicated. Images of colony formation, cell
cycle distribution, cell apoptosis, Western blot, and immunostain-
ing results from representative experiments are presented. The
figures were created using Adobe PhotoshopH CS graphics
program. All data were analyzed by a paired t-test using SPSS
11.0 software. Differences were considered statistically significant
at P,0.02.
Acknowledgments
We are grateful to Dr. Zhenhua Xie and Dr. Fangqi Zhen for excellent
technical support. We thank Dr. Jin Zhou and Pei Zhang for technical
assistance and carefully reading the manuscript. We thank Enying Wu for
helpful comments on the manuscript.
Author Contributions
Conceived and designed the experiments: CPG HBL LQH. Performed the
experiments: CPG KWL HBL YZ SNS QZ. Analyzed the data: CPG
KWL HBL HBC LQH. Contributed reagents/materials/analysis tools:
HBL YZ HBC LQH. Wrote the paper: CPG KWL LQH.
References
1. Schiffman MH, Brinton LA (1995) The epidemiology of cervical carcinogenesis.
Cancer 76: 1888–1901.
2. Durst M, Gissmann L, Ikenberg H, zur Hausen H (1983) A papillomavirus DNA
from a cervical carcinoma and its prevalence in cancer biopsy samples from
different geographic regions. Proc Natl Acad Sci U S A 80: 3812–3815.
3. Steele C, Shillitoe EJ (1991) Viruses and oral cancer. Crit Rev Oral Biol Med 2:
153–175.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999)
Human papillomavirus is a necessary cause of invasive cervical cancer
worldwide. J Pathol 189: 12–19.
5. Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R (2008) HPV E7 contributes to
the telomerase activity of immortalized and tumorigenic cells and augments E6-
induced hTERT promoter function. Virology 375: 611–623.
6. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, et al. (2000) Immunotherapy of a
human papillomavirus (HPV) type 16 E7-expressing tumour by administration
of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin
(BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121: 216–225.
7. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, et al. (2002)
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus
expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7
genes, in women with progressive cervical cancer. Clin Cancer Res 8:
3676–3685.
8. Veldman T, Horikawa I, Barrett JC, Schlegel R (2001) Transcriptional
activation of the telomerase hTERT gene by human papillomavirus type 16
E6 oncoprotein. J Virol 75: 4467–4472.
9. Nishimura A, Nakahara T, Ueno T, Sasaki K, Yoshida S, et al. (2006)
Requirement of E7 oncoprotein for viability of HeLa cells. Microbes Infect 8:
984–993.
10. Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma
virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.
Science 243: 934–937.
11. Boyer SN, Wazer DE, Band V (1996) E7 protein of human papilloma virus-16
induces degradation of retinoblastoma protein through the ubiquitin-proteasome
pathway. Cancer Res 56: 4620–4624.
12. Gonzalez SL, Stremlau M, He X, Basile JR, Munger K (2001) Degradation of
the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7
oncoprotein is important for functional inactivation and is separable from
proteasomal degradation of E7. J Virol 75: 7583–7591.
13. Gammoh N, Grm HS, Massimi P, Banks L (2006) Regulation of human
papillomavirus type 16 E7 activity through direct protein interaction with the E2
transcriptional activator. J Virol 80: 1787–1797.
14. Zhang B, Chen W, Roman A (2006) The E7 proteins of low- and high-risk
human papillomaviruses share the ability to target the pRB family member p130
for degradation. Proc Natl Acad Sci U S A 103: 437–442.
15. Caldeira S, Dong W, Tommasino M (2005) Analysis of E7/Rb associations.
Methods Mol Med 119: 363–379.
16. Wu EW, Clemens KE, Heck DV, Munger K (1993) The human papillomavirus
E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on
the retinoblastoma tumor suppressor protein. J Virol 67: 2402–2407.
17. Avvakumov N, Torchia J, Mymryk JS (2003) Interaction of the HPV E7 proteins
with the pCAF acetyltransferase. Oncogene 22: 3833–3841.
18. Huang SM, McCance DJ (2002) Down regulation of the interleukin-8 promoter
by human papillomavirus type 16 E6 and E7 through effects on CREB binding
protein/p300 and P/CAF. J Virol 76: 8710–8721.
19. DeMasi J, Huh KW, Nakatani Y, Munger K, Howley PM (2005) Bovine
papillomavirus E7 transformation function correlates with cellular p600 protein
binding. Proc Natl Acad Sci U S A 102: 11486–11491.
20. Huh KW, DeMasi J, Ogawa H, Nakatani Y, Howley PM, et al. (2005)
Association of the human papillomavirus type 16 E7 oncoprotein with the 600-
kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci U S A
102: 11492–11497.
21. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, et al. (2004)
Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:
11451–11460.
22. Shillitoe EJ, Kamath P, Chen Z (1994) Papillomaviruses as targets for cancer
gene therapy. Cancer Gene Ther 1: 193–204.
23. Nauenburg S, Zwerschke W, Jansen-Durr P (2001) Induction of apoptosis in
cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7
oncoprotein. FASEB J 15: 592–594.
24. Stanley M (2003) Chapter 17: Genital human papillomavirus infections–current
and prospective therapies. J Natl Cancer Inst Monogr. pp 117–124.
25. Sima N, Wang S, Wang W, Kong D, Xu Q, et al. (2007) Antisense targeting
human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and
senescence in SiHa cervical carcinoma cells. Gynecol Oncol 106: 299–304.
26. Knapp AA, McManus PM, Bockstall K, Moroianu J (2009) Identification of the
nuclear localization and export signals of high risk HPV16 E7 oncoprotein.
Virology 383: 60–68.
27. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, et al. (1985)
Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma
of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3: 1079–1085.
28. Rose PG, Blessing JA, Gershenson DM, McGehee R (1999) Paclitaxel and
cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma
Table 2. Primer sequences for real-time PCR.
Cyclin E1 For 59-GCAGCGAGCAGGAGACAGA-39 PRb For 59-TCTACCTCCCTTGCCCTGTTT-39
Cyclin E1 Rev 59-GCTGCTTCCACACCACTGTCTT-39 PRb Rev 59-CAGAAGGCGTGCACAGAGTGT-39
Cyclin A For 59-GTTTCCCCAATGCTGGTTGA-39 16E7 For 59 -CG GAATTCCCACCATG CAT GGA GAT ACA CCT ACA-39
Cyclin ARev 59-AACCAAAATCCGTTGCTTCCT-39 16E7Rev 59-CG GGATCCCGTGG TTT CTG AGA ACA GAT GG-39
Cyclin D1For 59-TGTTACTTGTAGCGGCCTGTTG-39 GAPDH For 59-CTCATGACCACAGTCCATGCC-39
Cyclin D1Rev 59-CCGGAGACTCAGAGCAAATCC-39 GAPDH Rev 59-GCCATCCACAGTCTTCTGGGT-39,
doi:10.1371/journal.pone.0017734.t002
Antagonist Peptide Targeting HPV16 E7
PLoS ONE | www.plosone.org 14 March 2011 | Volume 6 | Issue 3 | e17734of the cervix: A Gynecologic Oncology Group study. Journal of Clinical
Oncology 17: 2676–2680.
29. Burnett AF, Roman LD, Garcia AA, Muderspach LI, Brader KR, et al. (2000) A
phase II study of gemcitabine and cisplatin in patients with advanced, persistent,
or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 76: 63–66.
30. Long HJ, Bundy BN, Grendys EC, Benda JA, McMeekin DS, et al. (2005)
Randomized phase III trial of cisplatin with or without topotecan in carcinoma
of the uterine cervix: A gynecologic oncology group study. Journal of Clinical
Oncology 23: 4626–4633.
31. Lowy DR, Schiller JT (2006) Prophylactic human papillomavirus vaccines. J Clin
Invest 116: 1167–1173.
32. Agosti JM, Goldie SJ (2007) Introducing HPV vaccine in developing countries–
key challenges and issues. N Engl J Med 356: 1908–1910.
33. Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers.
Vaccine 24 Suppl 3: S3/11–25.
34. Banks L, Edmonds C, Vousden KH (1990) Ability of the HPV16 E7 protein to
bind RB and induce DNA synthesis is not sufficient for efficient transforming
activity in NIH3T3 cells. Oncogene 5: 1383–1389.
35. Banks L, Barnett SC, Crook T (1990) HPV-16 E7 functions at the G1 to S phase
transition in the cell cycle. Oncogene 5: 833–837.
36. Helt AM, Galloway DA (2001) Destabilization of the retinoblastoma tumor
suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell
cycle arrest in human keratinocytes. J Virol 75: 6737–6747.
37. Huh K, Zhou X, Hayakawa H, Cho JY, Libermann TA, et al. (2007) Human
papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin
ligase complex, which contributes to degradation of the retinoblastoma tumor
suppressor. J Virol 81: 9737–9747.
38. Wang J, Sampath A, Raychaudhuri P, Bagchi S (2001) Both Rb and E7 are
regulated by the ubiquitin proteasome pathway in HPV-containing cervical
tumor cells. Oncogene 20: 4740–4749.
39. Berezutskaya E, Yu B, Morozov A, Raychaudhuri P, Bagchi S (1997)
Differential regulation of the pocket domains of the retinoblastoma family
proteins by the HPV16 E7 oncoprotein. Cell Growth Differ 8: 1277–1286.
40. Ikeda MA, Jakoi L, Nevins JR (1996) A unique role for the Rb protein in
controlling E2F accumulation during cell growth and differentiation. Proc Natl
Acad Sci U S A 93: 3215–3220.
41. Moberg K, Starz MA, Lees JA (1996) E2F-4 switches from p130 to p107 and
pRB in response to cell cycle reentry. Mol Cell Biol 16: 1436–1449.
42. Sardet C, Vidal M, Cobrinik D, Geng Y, Onufryk C, et al. (1995) E2F-4 and
E2F-5, two members of the E2F family, are expressed in the early phases of the
cell cycle. Proc Natl Acad Sci U S A 92: 2403–2407.
43. Liu X, Clements A, Zhao K, Marmorstein R (2006) Structure of the human
Papillomavirus E7 oncoprotein and its mechanism for inactivation of the
retinoblastoma tumor suppressor. J Biol Chem 281: 578–586.
44. Helt AM, Galloway DA (2001) Destabilization of the retinoblastoma tumor
suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell
cycle arrest in human keratinocytes. Journal of Virology 75: 6737–6747.
45. Clemens KE, Brent R, Gyuris J, Munger K (1995) Dimerization of the human
papillomavirus E7 oncoprotein in vivo. Virology 214: 289–293.
46. Ohtani K, DeGregori J, Nevins JR (1995) Regulation of the cyclin E gene by
transcription factor E2F1. Proc Natl Acad Sci U S A 92: 12146–12150.
47. Henglein B, Chenivesse X, Wang J, Eick D, Brechot C (1994) Structure and cell
cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad
Sci U S A 91: 5490–5494.
48. XJ XZS (2009) Fast and Almost 100% Efficiency Site-directed Mutagenesis by
The Megaprimer PCR Method. PROGRESS IN BIOCHEMISTRY AND
BIOPHYSICS 36: 6.
49. Dona MG, Giorgi C, Accardi L (2007) Characterization of antibodies in single-
chain format against the E7 oncoprotein of the human papillomavirus type 16
and their improvement by mutagenesis. BMC Cancer 7: 25.
50. Niwa H, Wentzel AL, Li M, Gooding WE, Lui VW, et al. (2003) Antitumor
effects of epidermal growth factor receptor antisense oligonucleotides in
combination with docetaxel in squamous cell carcinoma of the head and neck.
Clin Cancer Res 9: 5028–5035.
51. Tom R, Bisson L, Durocher Y (2008) Transfection of Adherent HEK293-
EBNA1 Cells in a Six-Well Plate with Branched PEI for Production of
Recombinant Proteins. Cold Spring Harbor Protocols.
52. De Falco G, Bellan C, Lazzi S, Claudio P, La Sala D, et al. (2003) Interaction
between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis
of AIDS-related neoplasms. Oncogene 22: 6214–6219.
53. Nie CL, Gao GL, Han J, Li H, Chen HP, et al. (2008) Human Papillomavirus
16 E6, E7 siRNAs Inhibit Proliferation and Induce Apoptosis of SiHa Cervical
Cancer Cells. Chinese Journal of Cancer Research 20: 301–306.
54. Williams JPST, Li B, Mulloy R, Dimova D, Classon M (2006) The
retinoblastoma protein is required for Ras-induced oncogenic transformation.
Mol Cell Biol 26: 13.
55. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL (2005) Global
analysis of proliferation and cell cycle gene expression in the regulation of
hematopoietic stem and progenitor cell fates. J Exp Med 202: 1599–1611.
56. Jares P, Campo E, Pinyol M, Bosch F, Miquel R, et al. (1996) Expression of
retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with
cyclinD1 (PRAD1/CCND1)mRNAlevelsand proliferative activity.Am JPathol
148: 1591–1600.
57. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Takahira T, et al. (2008)
Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special
reference to utility of pRB immunoreactivity in differential diagnosis of
rhabdomyosarcoma subtype. J Cancer Res Clin Oncol 134: 1097–1103.
Antagonist Peptide Targeting HPV16 E7
PLoS ONE | www.plosone.org 15 March 2011 | Volume 6 | Issue 3 | e17734